Pre-mRNA splicing is a key control point in human gene expression. Disturbances in splicing due to mutation or aberrant splicing regulatory networks lead to dysregulated protein expression and contribute to a substantial fraction of human disease. Several classes of active and selective splicing modulator compounds have been recently identified, thus proving that pre-mRNA splicing is a viable target for therapy. We describe herein the identification of BPN-15477, a novel splicing modulator compound, that restores correct splicing of exon 20 in the Elongator complex protein 1 (ELP1) gene carrying the major IVS20+6T>C mutation responsible for familial dysautonomia. We then developed a machine learning approach to evaluate the therapeutic potential of BPN-15477 to correct splicing in other human genetic diseases. Using transcriptome sequencing from compound-treated fibroblast cells, we identified treatment responsive sequence signatures, the majority of which center at the 5' splice site of exons whose inclusion or exclusion is modulated by SMC treatment. We then leveraged this model to identify 155 human disease genes that harbor ClinVar mutations predicted to alter pre-mRNA splicing as potential targets for BPN-15477 treatment. Using in vitro splicing assays, we validated representative predictions by demonstrating successful correction of splicing defects caused by mutations in genes responsible for cystic fibrosis (CFTR), cholesterol ester storage disease (LIPA), Lynch syndrome (MLH1) and familial frontotemporal dementia (MAPT). Our study shows that deep learning techniques can identify a complex set of sequence signatures and predict response to pharmacological modulation, strongly supporting the use of in silico approaches to expand the therapeutic potential of drugs that modulate splicing.
RNA splicing is a complex and tightly regulated process that removes introns from pre-mRNA transcripts to generate mature mRNA. Differential processing of pre-mRNA is one of the principal mechanisms generating diversity in different cell and tissue types. This process can give rise to functionally different proteins and can also generate mRNAs with different localization, stability and efficiency of translation through alternative splicing of UTRs. RNA splicing requires the widely conserved spliceosome machinery along with multiple splicing factors 1 . The splicing reaction is directed by specific sequences, including the 5' and 3' splice sites, the intron branch point, and splice site enhancers and silencers found in both exons and introns 2 . Changes in the sequence of these elements, through inherited or sporadic mutations, can result in deficient or aberrant splice site recognition by the spliceosome. Disruption of splicing regulatory elements can generate aberrant transcripts through complete or partial exon skipping, intron inclusion or mis-regulation of alternative splicing, while mutations in the UTRs may affect transcript localization, stability or efficiency of translation. Mutations that alter mRNA splicing are known to lead to many human monogenic diseases including spinal muscular atrophy (SMA), neurofibromatosis type 1 (NF1), cystic fibrosis (CF), familial dysautonomia (FD), Duchenne muscular dystrophy (DMD) and myotonic dystrophy (DM), as well as contribute to complex diseases such as cancer and diabetes [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . The emergence of high throughput sequencing of large disease cohorts [19] [20] [21] , and the remarkable efforts to aggregate and annotate these mutations in an accessible infrastructure such as ClinVar 22 , now provides an unprecedented opportunity to apply novel deep learning approaches to predict mutations that affect pre-mRNA splicing 23 . The potential of developing such models will continue to increase as next generation transcriptome sequencing (RNASeq) data are amassed and curation of the associated mutational processes matures [23] [24] [25] [26] .
New therapeutic approaches aimed at correction of pre-mRNA splicing defects, including antisense oligonucleotides, splicing modulator compounds (SMCs), and modified exon-specific U1 small nuclear RNA, have shown significant promise in many diseases [27] [28] [29] [30] [31] [32] [33] [34] [35] . SMCs are attractive because they can be optimized for broad tissue distribution and are orally administered 27, 36, 37 . With advances in precision medicine and the capability to discover patientspecific mutations, there is strong impetus to develop new methods to predict if a drug might be beneficial in a specific patient. Deep learning techniques offer the potential to accomplish this at scale by integrating genomic data with annotation databases and relevant information about mutational mechanisms 38 . Deep learning models have been successfully applied to a spectrum of biological topics, including genotype-phenotype correlation studies 39 , identification of disease biomarkers 40 , and identification of protein binding motifs 41 . Here, we applied and optimized a specific deep convolutional neural network (CNN) to discover motifs that that are likely to be responsive to BPN-15477, a potent SMC of the ELP1 pre-mRNA carrying the major FD splice mutation IVS20+6T>C. We identified 155 genes harboring pathogenic ClinVar mutations, each predicted to disrupt pre-mRNA splicing, that could be corrected by BPN-15477 treatment, and validated several using minigenes or patient cells.
These studies suggest that the integration of genomic information, clinical annotation of disease associated variants, and deep learning techniques have significant potential to predict therapeutic targeting for precision medicine.
Results

Discovery of the splicing modulator BPN-15477.
Several small-molecules have been developed to selectively modulate the splicing of specific pre-mRNAs, offering potential new treatments for SMA and FD 27, 36, 37, [42] [43] [44] [45] . One such compound, kinetin (6-furfurylaminopurine), was previously shown to promote exon 20 inclusion in the Elongator complex protein 1 gene (ELP1, MIM: 603722) in FD 44, 46 . Although kinetin is a naturally occurring compound with a safe absorption, distribution, metabolism, and excretion (ADME) profile, very high doses are necessary to achieve modest ELP1 splicing correction in vivo 47, 48 . As part of the NIH Blueprint Neurotherapeutics Network we identified a new class of highly potent SMCs that selectively modulate ELP1 pre-mRNA splicing and increase the inclusion of exon 20 49 . Through further optimization we identified BPN-15477 ( Fig.1a ), a compound that increases full-length ELP1 mRNA by increasing exon 20 inclusion. BPN-15477 is significantly more potent and efficacious than kinetin in our luciferase splicing assay ( Fig.1b ) and it rescues ELP1 splicing in FD patient cell lines ( Fig.1c ).
Evaluation of BPN-15477 on transcriptome splicing.
To estimate the influence of BPN-15477 on transcriptome-wide splicing, we treated six wildtype (WT) human fibroblast cell lines with 30 μM BPN-15477 or vehicle (DMSO) for seven days and performed RNA-seq to evaluate changes in exon inclusion (Supplementary Table 1 ). Splicing differences were determined by counting the RNASeq reads covering two junctions of three consecutive exons (exon triplets) and by comparing the change in percent spliced-in (ΔPSI or Δψ) of the middle exon after treatment ( Fig. 2a , see Methods) 50, 51 . We identified 934 exon triplets that showed differential middle exon inclusion or exclusion in response to BPN-15477 treatment; 254 with increased exon inclusion (Δψ ≥ 0.1 and FDR < 0.1), and 680 with increased exon exclusion (Δψ ≤ -0.1 and FDR < 0.1, Fig 2b and Supplementary Table 2 ). BPN-15477 modulates splicing selectively as we observed splicing changes in only 0.58% of all expressed triplets (934 out of 161,097 expressed triplets). To experimentally confirm the accuracy of the PSI changes measured by RNASeq, we performed independent treatment experiments and evaluated exon inclusion using RT-PCR ( Fig. 2d-g) and found the estimated percent exon inclusion to be remarkably consistent with the calculated Δψ values (Fig. 2c ).
Convolutional neural network identifies sequence signatures responsible for BPN-15477 response.
Pre-mRNA splicing is regulated by both exonic and intronic sequence elements. These sequences govern interaction with the spliceosome and splicing factors and regulate the fate of exon recognition and inclusion 2, 52 . We hypothesized that sequence signatures within the exon triplets are a key determinant of drug responsiveness. To identify the sequence motifs, we trained a CNN model using the inclusion-response set (254 exon triplets), exclusion-response set (680 exon triplets) and the unchanged-response set (382 exon triplets with two expressed isoforms, Δψ < 0.01 and FDR ≥ 0.1, Supplementary Table 2 ). The network consisted of two layers of convolutions with a total of 2.5 million trainable parameters ( Supplementary Fig. 1a) and was optimized for predicting splicing changes in every given exon triplet after BPN-15477 treatment.
Our model achieved an average area under the curve (AUC) of 0.85 and identified thirty-nine 5-mer motifs that best explain drug responsiveness (Supplementary Figs. 1b-c and 2). Twelve of these motifs explained 94.87% of the AUC, each of which altered more than 0.1 of AUC for at least one class of prediction ( Fig. 3a) . Importantly, analysis of these motifs revealed that proximity to, and in many cases as part of, the 5' splice site of the middle exon had the largest influence in modulating treatment response ( Fig. 3b, Supplementary Fig. 3a ). To assess the robustness of the motifs identified by our CNN model, we compared the similarities of the twelve CNN-identified motifs with the most enriched five-nucleotide combinations (5-mer) at 5' splice sites of the middle exons in our training set. The 5-mer sequence enrichment analysis for nucleotides at positions -3 to +7 of 5' splice sites agreed with motifs identified by the CNN model ( Supplementary Fig. 3b ). Examination of our predicted motifs, combined with the 5mer and positional analysis, shows that the 5' splice sites of responsive exons are noncanonical. Therefore, we evaluated the strength of the four triplet splice sites using MaxEntScan 53 and found that the 5' splice site of the middle exon is significantly weaker when exon inclusion is enhanced by treatment ( Fig. 3c ). These results are consistent with previous findings that support the role of this class of SMCs in promoting the recruitment of U1 snRNP to non-canonical 5' splice sites 45, 46 .
We next sought to determine if our CNN model could predict treatment response in mutated exon triplets. We generated minigenes for treatment responsive alternatively spliced triplets in PARP6, SETD5 and CPSF7. These genes were chosen because their genomic triplet length enabled evaluation in an appropriate splicing vector. We mutated nucleotides in silico between positions +2 to +6 in the 5' splice site of each triplet and used our CNN model to predict treatment response. Mutations predicted to be responsive were introduced into the minigenes and splicing evaluated by RT-PCR. In all three minigene splicing assays, the RT-PCR data confirmed our CNN model predictions for mutant triplets ( Fig. 3d -e, Supplementary Fig. 3c ).
Therefore, our CNN model will allow us to evaluate the potential therapeutic value of BPN-15477 on human splicing mutations.
Identification of potential therapeutic targets of BPN-15477.
To evaluate the predictive power of our CNN model to determine which human diseasecausing mutations might respond to treatment with BPN-15477, we first identified the pathogenic mutations that alter splicing in ClinVar. We considered all 89,642 annotated pathogenic or likely-pathogenic mutations (CV-pMUTs) and predicted their influence on splicing using SpliceAI 23 . We found that ~20% of all CV-pMUTs are predicted to alter splicing within 5 kb of the mutation, and that ~80% of these disrupt Ensembl-annotated splice sites (GRCh37 version 75). As expected, the CV-pMUTs disrupting annotated splice sites were substantially closer to the splicing junction than the overall CV-pMUTs ( Fig. 4b ); ~98% of them were within 75bp. This observation confirms that our 100 bp training regions UI1, I1X, XI2 and I2D captured the majority of the potentially targetable pathogenic splicing alterations.
We next used our CNN model to predict which genes harboring CV-pMUTs might respond to BPN-15477 treatment. The 14,272 CV-pMUTs that disrupt annotated splice sites are mapped to 11,616 exon triplets, and our CNN model predicted that 271 of these triplets should be responsive to BPN-15477 treatment ( Supplementary Table 3 ). Therefore, our analysis identified 155 genes that harbor 214 annotated disease-causing mutations that could be targets for splicing correction using BPN-15477. The responsive genes containing the top 20 most frequent mutations and their associated human diseases are shown in Table 1 (gnomAD v2.1.1). Examination of Table 1 demonstrates the remarkable therapeutic potential of this class of splicing modulators.
Experimental validation of new therapeutic targets for BPN-15477
To evaluate whether BPN-15477 ameliorates aberrant splicing events, we searched for available human cell lines carrying the splicing mutations predicted to respond to our treatment (Supplementary Table 3 ). From the Coriell cell repository we were able to obtain a cell line with the c.894G>A mutation in the LIPA gene (Table 1) 54 . Mutations in LIPA cause both the severe infantile-onset Wolman disease and the milder late-onset cholesterol ester storage disease (CESD) [55] [56] [57] (MIM# 278000) 58 . The c.894G>A mutation leads to skipping of exon 8 and is responsible for the milder CESD. This is the most common LIPA gene mutation and it is found in about half of individuals with LAL deficiency 59 . To validate the treatment effect on the splicing of exon 8, patient cells were treated with 60 µM of BPN-15477 for 24 hours. As predicted, the treatment promoted the inclusion of exon 8, with mutated cells showing a 10% increase in normal transcript levels, which would lead to increased functional lipase A protein in patients ( Fig. 4c 3) . To overcome the limitations in available patient cell lines harboring specific splicing mutations, we prioritized our experimental validations based on the availability of minigene constructs. We obtained HEK293 cells stably expressing a minigene containing the full length CFTR coding sequence carrying a c.2988G>A mutation and flanking introns ( Supplementary table 3) 60 . This mutation is associated with abnormal CFTR function and causes a mild form of CF (MIM# 219700) 61 . Treatment with BPN-15477 increased exon 18 inclusion by 10%, confirming our CNN model prediction ( Fig. 4d ). This is exciting since a small increase in functional CFTR protein is associated with a significant improvement in patient phenotype. We also generated a MLH1 minigene spanning exons 16 to 18 harboring the c.1989 G>A mutation ( Supplementary table 3) , which leads to hereditary nonpolyposis colorectal cancer (HNPCC) or Lynch syndrome (MIM# 120435) and to skipping of exon 17 14, 62 . As predicted, the treatment significantly increased exon 17 inclusion in cell lines expressing the mutated minigene (Fig 4e, Supplementary Table 3 ).
Finally, to validate the utility of our treatment to promote exon skipping as a therapeutic modality, we searched for drug responsive disease-causing mutations that lead to abnormal middle exon inclusion. The MAPT gene is associated with familial frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17, MIM# 600274) [63] [64] [65] [66] . In healthy human brains, the alternative splicing of MAPT exon 10 is strictly regulated to maintain equal amounts of the 3R (exon 10 skipped) and 4R (exon 10 retained) tau isoforms. Disruption of this balance by increased 4R tau increases the risk of developing FTD. The c.1866 +3 G>A mutation, commonly referred to IVS10 +3, in the MAPT gene increases the inclusion of exon 10 and is associated with FTDP-17. Our CNN model predicted that the mutated sequence would be responsive to BPN-15477 and the treatment would promote exon 10 exclusion, thereby potentially restoring 3R/4R balance (Supplementary Table 3 ). We generated HEK293 cells stably expressing a MAPT minigene encompassing exons 9 to 11 and partial introns 9 and 10 with both the wild type sequence and the c.1866 +3 G>A mutation. As predicted, treatment with BPN-15477 led to a significant reduction of exon 10 inclusion in the wild type MAPT transcript. Unfortunately, introduction of the c.1866 +3 G>A mutation in the minigene context completely disrupted exon 10 skipping in both the DMSO and BPN-15477 treated minigenes ( Supplementary Fig. 4 ). However, it is known that in the human brain the c.1866 +3G>A mutation "leaks" a detectable amount of 3R tau isoform 67 , suggesting that treatment with a splicing modulator in vivo might still increase the level of 3R tau.
Given the importance of identifying therapeutics that modulate the 3R/4R tau ratio, combined with our demonstration that BPN-15477 can promote skipping of MAPT exon 10, we next evaluated the most common MAPT mutation, a C to T substitution in intron 10, c.1866+16C>T, commonly called IVS10 +16. Although this mutation increases inclusion of exon 10 63 , it did not appear in our list of responsive mutations because SpliceAI did not correctly predict its effect on splicing. We applied our CNN model to the MAPT c.1866+16C>T exon triplet, which predicted that BPN-15477 would promote exon 10 exclusion in the mutated triplet. Generation and evaluation of both wild type and mutant minigenes confirmed our prediction (Fig 4f) .
Taken together, these results suggest that BPN-15477 and other SMCs of this class might be an effective therapy for reducing the inclusion of exon 10 in MAPT, thereby delaying or ameliorating disease symptoms in patients carrying mutations that disrupt the balance of exon 10 inclusion. Our success in validating several of our CNN model predictions in both human cells and minigenes demonstrates that deep learning methods can be effectively applied to explore new therapeutic targets for known splicing modulators, and further sets the stage for evaluating their effectiveness across a wide range of human genetic diseases.
Discussion
The development of drugs that can increase the amount of normal transcript through modulating RNA splicing in patients is a new, precisely targeted treatment approach aimed directly at the primary molecular disease mechanism without altering the genome. The recent success of splicing modulation therapies for DMD (exondys 51) and SMA (nusinersen, risdiplam rg7800, branaplam) 42, 43 has validated the utility of splicing modification as a valuable therapeutic strategy for human disorders. Here, we have identified a novel compound, BPN-15477, that corrects splicing of ELP1 both in a minigene system and in FD patient cell lines.
We have demonstrated that BPN-15477 is a useful tool compound to study the effect of SMCs on splicing and its further optimization will lead to new therapeutic interventions for other human splicing disorders.
To determine the potential of BPN-15477 to correct splicing in other genes, we developed a machine learning approach that uses sequence signatures to predict targetable splicing defects.
Our CNN model identified a total of thirty-nine 5-mer motifs important for drug response, with twelve motifs accounting for most of the BPN-15477 sensitivity when motifs are located close to the 5' splice site. Evaluation of splice site strength in drug responsive triplets where middle exon inclusion is increased showed that these exons have weaker 5' splice sites, a finding consistent with the previously described mechanism of action of our SMCs. We have reported that the splicing defect characteristic of FD is due to the weak definition of ELP1 exon 20 and the kinetin-analog RECTAS was shown to promote the recognition of ELP1 exon 20 through the recruitment of U1 snRNP at the 5' splice site 45, 68 . Our CNN model predictions, combined with these previously published observations, strongly suggest that our SMCs act by promoting recognition of weakly defined exons.
Application of our CNN model to all ClinVar pathogenic mutations that disrupt splicing identified 214 human disease-causing mutations in 155 unique genes as potential therapeutic targets of BPN-15477, proving that deep learning models are a powerful approach to explore novel therapeutic targets for drugs that modify RNA splicing. As proof of principle, we validated the treatment effect on splicing for several disease-causing mutations using patient cell lines or minigenes, and demonstrate the potential therapeutic feasibility of targeting splicing in patients with cystic fibrosis (CFTR), cholesterol ester storage disease (LIPA), Lynch syndrome (MLH1) and familial frontotemporal dementia (MAPT). These findings could have significant impact for patients carrying these mutations. For example, Wolman disease and CESD are both caused by mutations in LIPA [55] [56] [57] . Wolman is lethal in infancy, whereas CESD patients have some residual enzyme activity and therefore have a milder clinical course.
Remarkably, patients with only 3% of the normal level of LIPA transcript have the much milder disease CESD, and we show that BPN-15477 increases exon 8 inclusion by 10% in a patient cell line, suggesting high potential therapeutic efficacy 58 . Similarly, our demonstration that BPN-15477 significantly increases correctly spliced CFTR transcript suggests that treatment could increase the production of functional CFTR ion channel in CF patients carrying the c.2988G>A mutation.
The ability of BPN-15477 to promote the exclusion of exon 10 in the MAPT gene is particularly exciting given its role in frontotemporal dementia. Many FTDP-linked MAPT mutations alter the splicing of tau exon 10, generally leading to an increase in exon 10 inclusion and increased expression of 4R tau isoforms, thereby disrupting the 3R (exon 10 skipped) and 4R (exon 10 retained) tau ratio [63] [64] [65] [66] . Herein we show significant exon 10 exclusion after treatment in both the WT and in the c.1866 +16 C>T minigene, which is the most common mutation associated with FTD in humans. From a therapeutic perspective, restoring the 3R/4R tau ratio has the potential to reduce or even eliminate unbound 4R tau. The results further suggest this SMC might be beneficial for other forms of FTD caused by gain of function mutations in exon 10, such as P301L, P301S or the S305N, since treatment could reduce the level of mutated transcript.
To our knowledge, this work represents the first application of a machine learning approach to analyze the global activity of a splicing modifier compound and identify new therapeutic targets. Our successful laboratory validation of several of our CNN model predictions establishes the promise of such approaches and may presage the future advances in precision medicine offered by deep learning techniques. In this study, we provide just one of the myriad examples by which new therapeutic targets for small molecules that target splicing can be discovered and broaden their value in treating human genetic disease.
Methods
Preparation of BPN-15477
(2-chloro-N-(4-pyridylmethyl)-7H-pyrrolo[2,3-d]pyrimidin-
4-amine)
BPN-15477 was manufactured by Albany Molecular Research Inc. (AMRI) and composition of matter is covered in International application No. PCT/US2016/013553. Synthesis and analytical data for BPN-15477 are described below. All materials used in the studies were >99% pure, as assessed by analytical methods including NMR, HPLC and LC/MS.
To a stirred suspension of 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine (1, 5001 mg, 26.60 mmol, 1.000 eq.), obtained from AstaTech Inc., Bristol, PA, in 1,4-dioxane (50.0 mL) was added 4-(aminomethyl)pyridine (2, 3420 mg, 3.20 mL, 31.6 mmol, 1.19 eq.) followed by N,Ndiisopropylethylamine (4450 mg, 6.00 mL, 34.1 mmol, 1.28 eq.) at room temperature. The reaction mixture was then heated to 90 C and stirred at that temperature overnight.
The reaction progress was monitored by LC-MS analysis of an aliquot of the reaction mixture.
After 12 h, ~6% starting material was detected by LC-MS. The reaction was quenched by water resulting in an emulsion. The mixture was filtered through Celite and then washed well with EtOAc (3x80 mL). The organic phase was separated and the aqueous phase was extracted with EtOAc (3x40 mL). The combined organic phases were washed with brine (50 mL) and then dried over sodium sulfate.
The volatiles were removed under reduced pressure to give the crude product as dark brown solid. To the crude solid was added EtOAc (100 mL). The mixture was then heated at reflux for 15 min before it was slowly cooled to room temperature. The resulting precipitate was collected by filtration, then washed well with cold EtOAc (30 mL) followed by diethyl ether Table S1 used for RNA sequence were cultured in D-MEM supplemented with 10% FBS and 1% penicillin/streptomycin. 
Treatment of Cultured Cells
Transfection
HEK293T cells were seeded in 6-well culture plates at 1.20 x10 6 cells/well in D-MEM,10% FBS, without antibiotics and incubated overnight to reach approximately 90% confluence the day after. Transfection was performed with FuGENE® HD Transfection Reagent (E2311, Promega) using the FuGENE-DNA ratio at 3.5:1 and following manufacturer protocol. After 4 hours of incubation at 37 °C, cells were plated at a density of 3x10 4 cells/well in a poly-Llysine coated 96-well plate for the dual luciferase assay or at the density of 8.5x10 5 cells/well into 6-well plates for minigene transfection. After 16 hours incubation at 37 °C, SMCs or DMSO were added at the desired concentrations as described in the next paragraph and kept in culture for other 24 hours.
Dual-luciferase splicing assay
Rluc-FD-Fluc plasmid used for the dual-luciferase splicing assay was derived using the ELP1 FD minigene 44 containing the ELP1 genomic sequence spanning exon 19-21 inserted into spcDNA3.1/V5-His Topo (Invitrogen). Firefly luciferase (FLuc) coding sequence was inserted immediately after exon 21 and renilla luciferase (RLuc) upstream of exon 19. Characterization of the assay has shown that RLuc is expressed each time a transcript is generated from the reporter plasmid, while FLuc is only expressed if exon 20 is included in the transcript, thereby keeping FLuc in-frame. Evaluation of FLuc/RLuc expression yields the percent exon inclusion in the splicing assays 49 . To perform the dual-luciferase assay HEK-293T were transfected with the described plasmid and treated with SMCs for 24 hours as illustrated above. After treatment the cells were washed once in PBS and lysed for 25 minutes at room temperature using 50µL well of passive lysis buffer (E1941, Promega). Luciferase activity was measured as previously described 49 .
RNA isolation and RT-PCR analysis
After treatment, cells were collected and RNA was extracted with QIAzol Lysis Reagent (79306, Qiagen) following the manufacturer's instructions. The yields of the total RNA for each sample were determined using a Nanodrop ND-1000 spectrophotometer.
Reverse transcription was performed using 0.5-1 µg of total RNA, Random Primers (C1181, 
RNASeq experiment
Six different human fibroblast cell lines from healthy individuals were obtained from Coriell Institute (Table S1 ) and cultured in D-MEM supplemented with 10% FBS and 1% penicillin/streptomycin. Cells were counted and plated in order to achieve semi-confluence after eight days. Twenty-four hours after plating, the medium was changed and cells were treated with BPN-15477 or DMSO to a final concentration of 30 µM and 0.5%, respectively.
DMSO was used as vehicle and the concentration of BPN-15477 was chosen based on our previous studies, since at this concentration BPN-15477 induces robust splicing changes and ELP1 protein increase. After seven days of treatment, cells were collected, and RNA was extracted using the QIAzol Reagent following the manufacturer's instructions. RNASeq libraries were prepared by the Genomic and Technology Core (GTC) at MGH using strandspecific dUTP method 69 . In brief, RNA sample quality (based on RNA Integrity Number, or RIN) and quantity was determined using the Agilent 2200 TapeStation and between 100-1000 ng of total RNA was used for library preparation. Each RNA sample was spiked with 1 µl of diluted (1:100) External RNA Controls Consortium (ERCC) RNA Spike-In Mix (4456740, ThermoFisher Scientific) alternating between mix 1 and mix 2 for each well in the batch.
Samples were then enriched for mRNA using polyA capture, followed by stranded reverse transcription and chemical shearing to make appropriate stranded cDNA inserts. Libraries were 
Differential splicing analysis
For each exon triplet in a certain biological replicate, ψ was calculated as 0.5*(R1+R2)/(0.5*(R1+R2)+R3) according to Fig.2a . The average ψ was calculated for treated and untreated condition, followed by the calculation of ψ change. For a certain exon triplet in a certain biological replicate, a 2x2 table was created, where the four cells of the table represent number of reads supporting middle exon inclusion and skipping before and after treatment.
Thus, for each exon triplet, totally six 2x2 tables were created for six biological replicates.
Cochran-Mantel-Haenszel test was applied to test whether there is an association between treatment and splicing across all replicates (namely whether the cross-replicate odds ratio is 1 or not). For each exon triplet, a p value of Cochran-Mantel-Haenszel test was reported.
Benjamini-Hochberg false-discovery-rate (BH FDR) correction was finally applied to p values of all triplets.
CNN model
Our CNN network contains two convolutional layers and one hidden layer ( Supplementary Fig.   1a ) and it was trained using Basset framework 41 there is no improvement of average of AUC in 10 consecutive epochs. In this study, we stopped at 12 th epoch to avoid overfitting ( Supplementary Fig. 1b ).
Examination of motif contribution
To examine motif contribution in classification, the validation set was used as model input. For each motif's contribution to be measured, its total output of the first convolutional layer from was manually set to the mean of all output. The model was then taken forward without tuning other parameters and the new AUC of each class was calculated. The contribution of that motif was measured as the difference between the new AUC and the original AUC of each class. All motifs were investigated in this way in turn. A motif whose contribution is more than 0 in any class is considered a true identified motif. A motif whose contribution is no less than 0.1 in any class is considered a top contributor in drug response prediction.
Analysis of positional importance
To examine each motif contribution in classification, the validation set was used as model input. For each motif whose positional importance was to be measured, the position-wise output of the first convolutional layer from that motif was manually set to the mean of all the convolutional outputs. The model was then taken forward without tuning other parameters and the new loss, measured by binary cross-entropy, of the model was calculated. The importance of that motif at that tuned position was measured as the difference between the new loss of the model and the original loss of the model. All the positions of that motif were investigated in turn. Each following motif was systematically investigated in the same fashion.
In silico saturated mutagenesis
For a given input sequence, each position was in silico mutated to the other three alternative nucleotides. The loss of the model using mutated sequences were calculated and compared to the loss derived from the original sequence. The maximum change of loss at each position was recorded. Nucleotides were drawn proportionally to the change of loss, beyond a minimum height of 0.25.
Standardized probability from prediction
To determine the final drug response (inclusion, exclusion or unchanged) from the prediction, the raw prediction score from the model was standardized. For each class, a cutoff representing 95% specificity of that class was identified on the validation set. The intermediate score of each class was calculated as the raw prediction score divided by the cutoff of that class. The standardized probability for each class was then calculated as the intermediate score divided by the sum of intermediate scores of three classes.
k-mer enrichment analysis
The sequences at -3 to +7 bp of the 5' splice sites of the middle exons for inclusion, exclusion and unchanged exon triplets were extracted. For each class, 5-mer enrichment was estimated against the other two classes using Discriminative Regular Expression Motif Elicitation (DREME) from THE MEME Suite with the parameter "-p, -n, -dna -e 0.05 and -k 5" 71 .
Splicing strength analysis
Splice strength was measured by maximum entropy model 53 . As described in the original study, the measurement in this paper takes the short sequence of 9bp and 23bp flanking splice junctions, depending on whether it's 5' or 3' side.
Candidate selection for minigene validation
To validate whether the CNN model correctly predicts BPN-15477 treatment response of mutated exon triplets, the following rules were applied to select suitable exon triplet: 1) exon triplets with a total length, including introns, less than 1.5 kb suitable for cloning; 2) exon triplets whose splicing changes were detectable in fibroblast RNASeq after BPN-15477 treatment, so that their drug responses could be used as positive control for the mutated minigenes; 3) The minigene recapitulates the same splicing change measured in the fibroblast by RNASeq to guarantee that the splicing process is intact in the minigene
Minigene generation
Wild-type and mutant double-stranded DNA (dsDNA) fragments, selected based on low nucleotide length and exon-skipping probability, were ordered through GENEWIZ 
SpliceAI prediction on ClinVar pathogenic mutations
The VCF file recording ClinVar (version 20190325) mutations was downloaded. The pathogenic/likely pathogenic mutations were extracted and fed to SpliceAI (https://github.com/illumina/SpliceAI). In the prediction from SpliceAI, any mutation with any SpliceAI score no less than 0.2 was considered alter splicing. Therefore, such mutation, together with its influenced splice junction (ISJ) and SpliceAI score were recorded.
Rescue definition and prediction
For an exon triplet, the coordinates of the two domains of the middle exon were compared to those ISJs discovered by SpliceAI. If either domain overlapped with an ISJ and its SpliceAI score indicated a splicing gain, the exon triplet was considered with promoted exon inclusion under that corresponding mutation. On the other hand, if the 5' splice site of the middle exon overlapped with an ISJ and its SpliceAI score indicated a splicing loss, the exon triplet was considered as exon skipping under that corresponding mutation.
Three kinds of rescue were considered: 1) if a mutated exon triplet was predicated (by SpliceAI) to cause exon skipping and it was predicted (by our CNN model) to have an inclusion response after BPN-15477 treatment; 2) if a mutated exon triplet was predicated (by SpliceAI) to cause promoted exon inclusion and it was predicted (by our CNN model) to have an exclusion response after BPN-15477 treatment; and 3) if a mutated exon triplet generated a pre-mature termination codon (PTC) inside middle exon and it was predicted (by our CNN model) to have an exclusion response after BPN-15477 treatment and its reading frame was not shifted after skipping the middle exon.
Allele frequency from gnomAD
VCF files for both human exome and genome sequencing were downloaded from gnomAD (v2.1.1). The corresponding ClinVar mutations were located in these VCF files via their SNP IDs. If the short variant was found only in exome or only in genome sequencing VCF, the reported minor allele frequency was then used. If short variant was found in both exome or in genome sequencing, the combined frequency was calculated as (AC1+AC2)/(AN1+AN2),
where AC1 and AC2 are the allele counts exome and genome sequencing respectively and AN1 and AN2 are the total sample sizes for exome and genome sequencing respectively.
Statistical analyses
For differential splicing analysis, Cochran-Mantel-Haenszel test was applied followed by FDR correction. An FDR < 0.1 and Δψ ≥ 0.1 was considered as inclusion-response after the treatment (Fig. 2b ). Any triplet with FDR < 0.1 and Δψ ≤ -0.1 was considered as exclusionresponse after the treatment (Fig. 2b) . Any exon triplet, whose ψ before-treatment range from 0.1 to 0.9 and ψ change is less than 0.01, was considered as unchanged-response. For Pearson correlation (Fig. 2c) , the grey zone indicates 95% confident intervals. The p values were then adjusted by Bonferroni correction. For splicing strength comparison (Fig. 3c ), the maximum entropy was compared among inclusion, exclusion and unchanged groups at each splice junction, using unpaired Welch's t test followed by Bonferroni correction. For the boxplots ( Fig. 3c ), the middle lines inside boxes indicate the medians. The lower and upper hinges correspond to the first and third quartiles. Each box extends to 1.5 times inter-quartile range (IQR) from upper and lower hinges respectively. Outliers were not shown. For RT-PCR comparison ( Fig. 3-4 ), unpaired Student's t test was applied. For the distance comparison (Fig.   4b ), the Kolmogorov-Smirnov (K-S) test was applied. All the tests are done in two-tailed. In all plots, the error bars indicate the 95% confident interval if not specified. In all plots, the significance levels were marked by * p < 0.05, ** p < 0.01 and *** p < 0.001, where the significance levels always refer to the adjusted p values if the adjustment was mentioned above. 
